We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Horiba Presents Comprehensive Range of Hematology, Hemostasis and Clinical Chemistry Analyzers at MEDLAB Middle East

By LabMedica International staff writers
Posted on 24 Jan 2022

Image: Horiba at MEDLAB Middle East 2022 (Photo courtesy of Horiba Medical)

Image: Horiba at MEDLAB Middle East 2022 (Photo courtesy of Horiba Medical)

Horiba Medical (Kyoto, Japan) presented its comprehensive hematology, hemostasis and clinical chemistry analyzer ranges, as well as its HELO Solution that meets all laboratory configuration needs at MEDLAB Middle East 2022.

At the 2022 edition of MEDLAB Middle East, Horiba displayed its Yumizen G Range of five hemostasis analyzers and a comprehensive reagents menu from routine to specialized tests. Also on display was Horiba’s new compact hematology system the Yumizen H550 that provides full walk-away capability to small-mid size laboratories. The Yumizen H550 is a compact hematology system with integrated sample rack auto loading that is designed to provide rapid testing and full hematology diagnosis. It provides the operator with a full walk-away capacity of 40 tubes with continuous loading. Based on proven and innovative technologies, it answers the need for a robust analyzer and requires no user maintenance. Horiba also displayed the Yumizen H2500, its new generation automated hematology analyzer that answers customers expectations of solid and reliable diagnostic technology as well as rapid and consistent results.

The focus at Horiba’s demonstrations at the event was on the company’s global hematology solution, the HELO Solution (HORIBA Evolutive Laboratory Organization). HELO is an innovative design solution covering all the needs of a high throughput automated hematology platform. Flexible and efficient, HELO is the optimum answer to the constant evolution of any laboratory. The HORIBA advanced technologies embedded in the Yumizen H2500/H1500 associated with over 30 years experience in Hematology diagnosis offer the highest analytical performances. Thanks to its data, tube management, waste, blood film and digitalization management capability, HELO not only addresses a lab’s needs, but helps them to optimize TAT, floor space and reagent storage.

Related Links:
Horiba Medical

Visit expo >

Gold Member

Clinical Chemistry Assay

Sorbitol Dehydrogenase (SDH)

Online QC Software
Acusera 24•7

New

Electrolyte Analyzer

CBS-4000 (CBS-400)

New

Automated Urinalysis Solution

UN-9000

Latest Medlab 2022 News

Channels

Clinical Chemistry

view channel

Image: Originally designed for lung cancer detection and resistance monitoring, the test also shows potential for identifying signals linked to pulmonary fibrosis (image credit: iStock)

Urine-Based Nanosensor Tracks Lung Cancer and Fibrosis Noninvasively

Lung cancer remains difficult to monitor for early progression and treatment resistance, while pulmonary fibrosis continues to pose major challenges for early diagnosis. Clinicians need repeatable, noninvasive... Read more

Blood-Based Alzheimer’s Test Gains CE Mark for Amyloid Pathology Detection

Alzheimer’s disease is the most common cause of dementia, yet confirmatory testing remains invasive and hard to access. Diagnosis currently takes an average of 3.5 years, and about 75% of people with dementia... Read more

FDA-Cleared Assay Enables Comprehensive Automated Testosterone Testing

Accurate evaluation of androgen status often requires concordant measurement of total testosterone, free testosterone, and sex hormone‑binding globulin. Reference methods such as equilibrium dialysis with... Read more

CE-Marked Blood Biomarker Test Advances Automated Alzheimer’s Diagnostics

Specialized care settings frequently evaluate patients aged 50 years and older who present with signs and symptoms of cognitive decline to determine whether amyloid pathology linked to Alzheimer’s disease... Read more

Molecular Diagnostics

view channel

Image: Researchers identified eight new DNA pattern signatures that could help refine diagnostics and guide targeted therapy in breast cancer (image credit: 123RF)

Breast Cancer-Specific Signatures Link Genome Instability to Outcomes

Genomic instability is a hallmark of cancer, but most genomic analyses have relied on broad signatures shared across multiple malignancies, limiting their precision for individual tumor types.... Read more

Whole-Genome MRD Test Detects Early Recurrence in Muscle-Invasive Bladder Cancer

Bladder cancer is among the most common malignancies in the United States, with about 85,000 new cases each year. The muscle-invasive form accounts for roughly one quarter of diagnoses and carries a high... Read more

Image: Researchers found that tumor DNA fragments in blood can reveal ongoing prostate cancer growth even when current tests show little change (image credit: Adobe Stock)

Blood Test Detects Early Nonresponse in Metastatic Prostate Cancer

Prostate cancer is the most common cancer in the U.K., with more than 64,000 men diagnosed and 12,000 deaths each year. For the roughly 10,000 men annually with advanced disease, early assessment of treatment... Read more

FDA-Cleared Genomic Profiling Assay Guides Treatment Selection in Solid Tumors

Datar Cancer Genetics (DCG; Nashik, India), a global precision oncology company, has announced that its tissue-based comprehensive genomic profiling (CGP) assay for all solid tumors, CellDx-Tissue, has received U.... Read more

Hematology

view channel

Image: Graphical abstract (Waclawiczek A, Leppä AM, Renders S, et al. Cell Stem Cell, 2026. doi:10.1016/j.stem.2026.04.012)

Stem Cell Biomarkers May Guide Precision Treatment in Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is an aggressive blood cancer that most often affects older adults and still carries a poor prognosis despite therapeutic advances. Venetoclax-based regimens have improved... Read more

Advanced CBC-Derived Indices Integrated into Hematology Platforms

Diatron, a STRATEC brand, has introduced six advanced hematological indices on its Aquila, Aquarius 3, and Abacus 5 hematology analyzers. The new Research Use Only (RUO) indices include Neutrophil-to-Lymphocyte... Read more

Blood Test Enables Early Detection of Multiple Myeloma Relapse

Bone marrow biopsies remain central to diagnosing and monitoring multiple myeloma, yet the procedure is painful, invasive, and often repeated over time. Older patients—who represent most new cases—can... Read more

Single Assay Enables Rapid HLA and ABO Genotyping for Transplant Matching

CareDx (Brisbane, CA, USA) has introduced AlloSeq Nano, a nanopore‑based HLA (human leukocyte antigen) and ABO genotyping solution unveiled at the European Federation for Immunogenetics (EFI) Conference 2026.... Read more

Immunology

view channel

Routine TB Screening Test May Reveal Immune Aging and Mortality Risk

Immune aging is associated with weaker responses to vaccination, greater risks of infection, and higher levels of inflammation. Leveraging routinely ordered laboratory tests to quantify that responsiveness... Read more

Biomarkers and Molecular Testing Advance Precision Allergy Care

Allergic diseases often present with similar symptoms but can be driven by distinct biological mechanisms, making standardized care inefficient for many patients. Historically, individuals with pollen... Read more

Image: Schematic of Mpox diagnostic methods.(A) Artificial intelligence (AI)-enhanced image classification can be leveraged to classify lesions concerning for Mpox, particularly in low resource settings where specialists (i.e., infectious disease specialists or dermatologists) are not available. (B) Clinical specimens (including nasal swabs, lesion swabs, or serum samples) can be used for molecular or biochemical confirmation of Mpox infection. (C) Rapidly, field-deployable devices or assays can be developed using various strategies(Mpox) diagnostic methods (Yilgic D, Ergonul O, Tasoglu S. Mpox diagnosis at POC. Trends in Biotechnology. DOI: 0.1016/j.tibtech.2025.04.015)

Point-of-Care Tests Could Expand Access to Mpox Diagnosis

Mpox outbreaks in non-endemic regions have underscored the need for rapid, accessible diagnostics to limit transmission. Polymerase chain reaction (PCR) remains the clinical reference, yet it depends on... Read more

Image: Graphical abstract (Turano PS, Akbulut E, Dewald HK, et al. Cell Reports (2026). DOI: 10.1016/j.celrep.2025.116795)

T-Cell Senescence Profiling May Predict CAR T Responses

Chimeric antigen receptor (CAR) T-cell therapy can deliver striking, durable remissions, yet many patients experience minimal or no benefit. The quality of patient-derived cytotoxic T lymphocytes used... Read more

Microbiology

view channel

Study Finds Hidden Mpox Infections May Drive Ongoing Spread

Mpox continues to circulate despite vaccination, and many cases show no known link to a symptomatic partner. The role of people without symptoms has remained uncertain, limiting clarity on how transmission persists.... Read more

Image: The initiative combines epidemiological and microbiological data with whole-genome sequencing to characterize circulating hospital lineages and resistance determinants (image credit: Shutterstock)

Large-Scale Genomic Surveillance Tracks Resistant Bacteria Across European Hospitals

Antimicrobial resistance (AMR) poses a growing threat to patient safety, with carbapenem-resistant Enterobacterales causing difficult-to-treat infections and leaving clinicians with limited therapeutic options.... Read more

Molecular Urine and Stool Tests Do Not Improve Early TB Treatment in Hospitalized HIV Patients

Tuberculosis is the leading cause of death among people living with HIV, and diagnosis in hospital settings remains difficult. Symptoms are often non-specific, disease can be extrapulmonary, and many patients... Read more

Image: Biosensor for tuberculosis detection (photo courtesy of UPV)

Rapid Antigen Biosensor Detects Active Tuberculosis in One Hour

Tuberculosis remains a major global health challenge and continues to drive significant morbidity and mortality. The World Health Organization’s 2024 global report cites it as the leading cause of death... Read more

Pathology

view channel

Image: Graphical Abstract (Eldad D. Shulman et al., AI-predicted spatial transcriptomics unlocks breast cancer biomarkers from pathology, Cell (2026). DOI: 10.1016/j.cell.2026.04.023)

Rapid AI Tool Predicts Cancer Spatial Gene Expression from Pathology Images

Gene expression profiling can inform tumor biology and treatment selection, but spatial assays remain costly and time-consuming. Results can take weeks and cost thousands of dollars, limiting large-scale... Read more

AI Pathology Test Receives FDA Breakthrough for Bladder Cancer Risk Stratification

Non–muscle invasive bladder cancer has highly variable outcomes, complicating surveillance and treatment planning. Risk assessment typically relies on stage, grade, and tumor size, leaving uncertainty... Read more

FDA Clears AI Digital Pathology Tool for Breast Cancer Risk Stratification

Risk assessment at diagnosis is central to guiding therapy for early-stage, hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) invasive breast cancer, where overtreatment... Read more

Image: Tissue sample spatial analysis (on left) and standard H&E image (on right) (Photo courtesy of QIMR Berghofer Medical Research Institute)

New AI Tool Reveals Hidden Genetic Signals in Routine H&E Slides

Pathologists worldwide rely on hematoxylin and eosin (H&E) slides to examine tissue architecture, yet these stains do not reveal the underlying molecular activity that often drives disease.... Read more

Technology

view channel

Point-of-Care Testing Enhances Health Literacy and Self-Management in Chronic Disease

Limited access to general practitioners and pathology services can delay diagnosis and monitoring for people in regional and remote communities. Rapid, on-the-spot testing can shorten turnaround times... Read more

Fully Automated Sample-to-Insight Workflow Advances Latent TB Testing

Latent tuberculosis remains a substantial testing workload for clinical laboratories as screening programs expand. Despite this growth, only about 40% of testing has shifted from traditional skin tests... Read more

Tumor-on-a-Chip Platform Models Pancreatic Cancer Treatment Response

Pancreatic cancer remains one of the hardest malignancies to treat because tumors are embedded within a dense microenvironment that shapes growth and therapy response. Standard laboratory models often... Read more

New Platform Captures Extracellular Vesicles for Early Cancer Detection

Early diagnosis remains the most effective way to reduce cancer mortality, yet many screening tools miss disease at its earliest stages. Biomarkers shed by tumors into blood and other fluids can be scarce... Read more

Industry

view channel

Image: Ozelle Wins German Innovation Award Gold (photo courtesy of Ozelle)

AI-Powered Multi-Functional Analyzer Wins German Innovation Award

Hematology services are increasingly delivered across distributed care settings, where limited staffing and complex workflows can extend turnaround times. Advanced morphology review still often depends... Read more

Partnership Aims to Bring Risk-Guided CKD Care to Health Systems

Chronic kidney disease (CKD) places a substantial clinical and financial burden on the United States. As health systems face growing pressure to detect risk earlier and manage progression proactively,... Read more

Roche to Acquire PathAI for Up to $1.05 Billion to Strengthen AI Diagnostics Portfolio

Roche has entered into a definitive merger agreement to acquire PathAI, a company focused on digital pathology and artificial intelligence for pathology laboratories and the biopharma industry.... Read more

FDA Clears Blood-Based Companion Diagnostic for Advanced Breast Cancer Therapy

Endocrine therapy resistance remains a significant challenge in estrogen receptor–positive, human epidermal growth factor receptor 2–negative (HER2-) advanced breast cancer, where tumor evolution can limit... Read more